Dr. Chidozie Victor Agu has 10+ years of experience in
platform assay development. He holds a Ph.D. in Metabolic Engineering from The
Ohio State University and MS and B.S. in Biotechnology and Biochemistry from the
University of Nigeria. His Ph.D. research focused on metabolic engineering and
microbial characterization for biofuel and fine chemical production from
non-food lignocellulosic biomass substrates. He developed a consolidated
bioprocess to improve biomass detoxification and butanol production from lignocellulose
hydrolysate, designed a recombinant enzyme-based high-throughput assay to
screen microbial mutant libraries for hyper butanol production, and contributed
to the development of purification workflow for 2,3-butanediol in an Ohio State
University/Peloton Energy project. Dr. Agu specializes in bioassay design and
optimization and currently focuses on developing biosensing assay platforms
for disease diagnosis at SPOC Proteomics. As Manager of Bioassay Development,
he contributed to the initial development of the multiplexed SPOC protein
biosensor platform, an NIH-funded project for high-throughput cell-free
protein expression, capture-purification, and kinetic screening. He continues
to oversee its verification and validation across new applications. He
contributed to development of other proprietary platforms, including a
field-effect transistor-based enzymatic reaction monitoring diagnostic device
and a solid-state nanopore-based genome sequencer.
Dr. Chidozie Victor Agu has 10+ years of experience in
platform assay development. He holds a Ph.D. in Metabolic Engineering from The
Ohio State University and MS and B.S. in Biotechnology and Biochemistry from the
University of Nigeria. His Ph.D. research focused on metabolic engineering and
microbial characterization for biofuel and fine chemical production from
non-food lignocellulosic biomass substrates. He developed a consolidated
bioprocess to improve biomass detoxification and butanol production from lignocellulose
hydrolysate, designed a recombinant enzyme-based high-throughput assay to
screen microbial mutant libraries for hyper butanol production, and contributed
to the development of purification workflow for 2,3-butanediol in an Ohio State
University/Peloton Energy project. Dr. Agu specializes in bioassay design and
optimization and currently focuses on developing biosensing assay platforms
for disease diagnosis at SPOC Proteomics. As Manager of Bioassay Development,
he contributed to the initial development of the multiplexed SPOC protein
biosensor platform, an NIH-funded project for high-throughput cell-free
protein expression, capture-purification, and kinetic screening. He continues
to oversee its verification and validation across new applications. He
contributed to development of other proprietary platforms, including a
field-effect transistor-based enzymatic reaction monitoring diagnostic device
and a solid-state nanopore-based genome sequencer.